asco.org5 天
For PR Professionals
This page contains important information for corporate and institutional public relations professionals about ASCO Meetings. Once an abstract is submitted to an ASCO Meeting, the abstract and study ...
asco.org2 天
T-cell redirected bispecific antibodies in relapsed and refractory multiple myeloma: A ...
NR- not reported NR*- not reached Clinical outcome data with use of bispecific antibodies.
asco.org5 天
Press Center
Welcome to ASCO’s Press Center. Find the latest news releases related to ASCO’s peer-reviewed journals, scientific meetings, and public policy-related statements and initiatives, as well as ...
asco.org3 天
Conflict of Interest (COI)
The American Society of Clinical Oncology (ASCO) is a professional oncology society committed to conquering cancer through research, education, prevention, and the delivery of high-quality patient ...
asco.org2 天
ASCO's Advocacy Toolkit
The Association for Clinical Oncology (ASCO) offers multiple ways for you and your colleagues to engage with policymakers and educate them on ASCO’s advocacy priorities, while leveraging your insights ...
asco.org5 天
Young Investigator Award
The Conquer Cancer Young Investigator Award (YIA) provides funding to promising investigators to encourage and promote quality research in clinical oncology. The purpose of this award is to fund ...
asco.org2 天
Efficacy and safety of surufatinib plus toripalimab in previously treated advanced tumors ...
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org6 天
ASCO Overview
Conquering cancer through research, education, and promotion of the highest quality patient care. ASCO is supported by its affiliate organization, Conquer Cancer, the ASCO Foundation, which funds ...
asco.org2 天
Tislelizumab plus chemotherapy as first-line treatment for unresectable, locally advanced ...
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org2 天
Feasibility of pharmacist co-management for patients prescribed oral anticancer therapy for ...
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org2 天
Long-term efficacy and safety of pembrolizumab with R-CHOP as first-line therapy for DLBCL.
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org2 天
POLARIX: A phase 3 study of polatuzumab vedotin (pola) plus R-CHP versus R-CHOP in patients ...
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...